Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: The combination of Dalpiciclib with physician-selected endocrine therapy|DRUG: Chemotherapy selected by the physician
Sponsor: Peking Union Medical College Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.